Sglt 2 denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for sglt2 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for SGLT2 Inhibitors

Aetna requires prior authorization (PA) for SGLT2 inhibitors as a standard formulary management tool. A "prior-auth-required" denial means the plan did not receive an approved PA before the prescription was dispensed or the claim was submitted — not that the patient is necessarily ineligible for coverage. The denial is administrative in nature and is resolved by submitting the required PA documentation.

PA approvals for SGLT2 inhibitors are routinely obtained when the clinical documentation clearly maps the patient's profile to each of Aetna's stated criteria.

## Federal Appeal Framework

• PA submission or internal appeal — if the PA was never submitted, submit it now; many plans process it concurrently with a formal appeal. If the PA was denied on clinical grounds, file a formal internal appeal. ERISA plans require Aetna to decide urgent pre-service appeals within 72 hours and standard pre-service appeals within 15 days (urgent) or 30 days (standard).
• External review (ACA §2719 / ERISA §503) — if Aetna denies your internal appeal, you are entitled to independent external review. The external-review window is generally approximately four months from the original adverse determination. Expedited review is available when delay would seriously jeopardize health.

## Documentation to Gather

• Aetna's current published PA criteria for SGLT2 inhibitors — download directly from Aetna's provider or member portal. Address every listed criterion in your submission.
• Prescriber letter of medical necessity — should state the diagnosis (with ICD-10 code), the specific SGLT2 inhibitor prescribed, the FDA-approved indication being treated, and how the patient's clinical profile meets each of Aetna's stated PA criteria.
• Diagnosis and comorbidity documentation — chart notes confirming the condition(s) being treated, particularly any cardiovascular, heart failure, or renal comorbidities relevant to the prescribed agent's indication.
• Prior-treatment history with dates and outcomes — a dated record of prior medications tried for the same indication, with documented responses or reasons for discontinuation, to address any step-therapy elements embedded in Aetna's PA criteria.
• Relevant lab or clinical values — objective chart data supporting the diagnosis and severity, without relying on specific numeric thresholds (leave threshold language to the prescriber's clinical judgment and Aetna's own published criteria).
• Applicable guideline organization support — a reference to the relevant guideline organization (e.g., ADA, ACC/AHA, KDIGO) that recommends the drug class for the indication, cited by organization name.

## Criteria-Mapping Structure

Submit a structured attachment that maps each PA criterion to the supporting evidence:

| Aetna PA Criterion | Supporting Chart Evidence | |---|---| | Diagnosis confirmed | [Diagnosis + ICD-10 + chart date + provider] | | Prior therapy required | [Drug, dates, outcome or reason not applicable] | | Indication-specific criterion | [Relevant chart fact] | | Prescriber type/specialty | [Provider credentials] |

## Key Argument

PA denials are procedural gates, not clinical judgments. When the clinical record is complete and each criterion is addressed in a structured, organized submission, approval rates are high. If Aetna's PA criteria contain elements that your chart clearly satisfies, make that alignment explicit and unambiguous — reviewers approve submissions that do the matching work for them.